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Many characteristics that define malignant tumors (Hanahan, and Weinberg, 2000) arise from 
their ability to change the way that cells around them respond.  They learn to generate signals 
that cause otherwise normal cells to behave in ways that suit their proliferative and metastatic 
tendencies.  They convince blood vessels to grow, they turn off killer immune cells, and they 
elicit growth signals from cells that otherwise wouldn’t provide them. 
One type of immune cell that often succumbs to tumor manipulation is the macrophage.  Since 
Virchow in 1863, scientists have recognized that these inflammatory cells did something to 
tumors that made things worse for patients.  Modern clinical science has uncovered strong links 
between these inflammatory cells and patient outcomes (Kacinski, 1995; Scholl, Lidereau, et al, 
1996).  Basic scientists have shown how breast tumors revert to developmental programs that 
invoke reciprocal macrophage-tumor interactions which enable tumor cell growth and survival as 
well as spread of these cells to other parts of the body (Condeelis, and Pollard, 2006). 
Other scientists have noted that macrophages and other classical cell types actually demonstrate 
a number of diverse phenotypes.  Tacke and colleagues (Tacke, and Randolph, 2006) have 
identified different subpopulations of monocytes (which are blood-borne macrophage 
precursors), each of which behave differently and respond differently to various challenges.  
These monocyte subsets have been characterized primarily using the Gr-1 antigen, with the 
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“classical,” inflammatory monocytes identified by high Gr-1 surface expression.  Recently, 
David Hume’s group (Sasmono, Ehrnsperger, et al, 2007) showed that a particular subset of 
neutrophils transcribed genes typically associated with macrophages.  This subset identified by 
their high Gr-1 expression. Other groups, working to characterize some of the bad macrophage 
players in tumor pathogenesis, have identified a subset of tumor associated macrophages which 
they have termed myeloid-derived suppressor cells (MDSCs) (Sica, and Bronte, 2007).  Once 
again, this subset was delineated by high Gr-1 expression.  There exists a possibility that these 
three cellular subsets may be intimately related.   
In the present studies, we wanted to explore the effects of macrophage ablation in a tumor model 
and the effects of altering levels of particular cellular subsets on tumor growth and metastasis.  
To do this, we made use of a previously characterized mouse model, the MAFIA (macrophage 
fas-induced apoptosis) mouse (Burnett, Kershen, et al, 2004) (Figure 1).  To create this mouse, 
Burnett and colleagues generated a construct which expressed an inducible suicide gene (Yang, 
Rozamus, et al, 2000) under the regulation of the M-CSF receptor promoter.  Administration of 
an engineered ligand (AP20187 (Jin, Zeng, et al, 2000)) induces apoptosis of cells which express 
the suicide gene—in this case, the macrophage.  This model provides us with a unique method 
for temporal ablation of mouse macrophages.   
Results 
Dimerizer administration effectively ablates tumor macrophages.  We wanted to verify that 
activation of the suicide gene could eliminate macrophages from the tumors of MMTV-PyMT 
transgenic mice.  To do so, we stained FFPE sections of tumors extracted from MAFIA-PyMT 
mice with antibodies directed at the F4/80 antigen.  Figure 2 shows the results of these 
experiments.  Both qualitative and quantitative analysis of these sections demonstrate a near-
complete elimination of F4/80+ cells from the tumors.  We note that macrophage numbers from 
the treated tumors always measure artificially high, since the macrophages that would normally 
destroy the F4/80+ apoptotic bodies have been eliminated.  These data confirm the validity of 
this model as a method for testing the effects of macrophage ablation on tumor progression. 
Macrophage ablation in MAFIA mice promotes tumor growth and metastasis.  To test the effects 
of macrophage ablation, we randomized ten-week old PyMT+ mice with or without the MAFIA 
transgene to treatment with dimerizer (AP20187) or vehicle (dimerizer diluent, see Materials and 
Methods).  After five weeks of treatment, we removed their tumors and weighed them to 
compare total tumor burden between groups.  As a group, MAFIA+ mice that received dimerizer 
(macrophages ablated) had larger tumors that mice that did not have the MAFIA transgene or 
that did not receive dimerizer (macrophages normal, Figure 3A).  
We removed the lungs from these same mice and mounted them whole, according to procedures 
outlined in Materials and Methods.  We imaged these lungs under a stereomicroscope equipped 
with a lighted stage to count the metastases.  Mice whose macrophages were ablated had 
significantly more metastases than mice with normal macrophage levels (Figure 3B). 
Macrophage apoptosis does not stimulate tumor growth.  One hypothesis proposed to explain the 
outcomes we observed is that massive apoptosis induced by administration of the dimerizer 
might create pools of apoptotic bodies that might stimulate tumor cells to grow and take on 
malignant characteristics.  To test this hypothesis, we performed three-dimensional tumor growth 
assays (TGAs) (Sasser, Mundy, et al, 2007) with the aid of Dr. Brett Hall’s lab at Nationwide 
Children’s Hospital.  Figure 4A shows data validating the use of the MET-1 cell line developed 
in the Hall lab.  Figure 4B shows the results of our experimental data.  Tumor cells were cultured 
for the first 48 hours alone or together with increasing numbers of bone-marrow –derived 
macrophages from MAFIA+ mice.  After 48 hours, we administered a dose of dimerizer to 
induce apoptosis in the macrophages.  From the graph, one can see that this apoptosis (or the 
drug itself) actually caused a decrease in the rate of tumor cell growth.  One can also see that, 
before treatment, tumor growth in this system decreased with increasing macrophage number.   
This observation may stem from a crowding effect of the macrophages on the tumor cells, 
although this would be very unlikely, especially at the lower macrophage denisities.  Taken in 
context with the other results shown in this study, these results suggest that some of the more 
mature macrophages may actually take on roles that negatively affect tumor growth.  
Macrophage ablation causes reactive monocytosis and stimulates extramedullary hematopoiesis.  
We removed blood and spleens from the mice in an effort to further characterize the effects of 
macrophage ablation on the hematopoietic system in these mice.  Spleens stained for F4/80 
(Figure 5A) showed a reduction in the number of macrophages and disruption of the splenic 
architecture, as was previously described (Burnett, Kershen, et al, 2004).  We also noted in these 
spleen samples several areas of extramedullary hematopoiesis (see arrows), suggesting a 
stimulus for blood cell production that could not be met by the bone marrow. 
CBC analysis on blood samples from these mice (Figure 5B) showed that nucleated cells, band 
neutrophils, segmented neutrophils, lymphocytes, and platelets were not significantly different 
between MAFIA+ mice treated with dimerizer and those treated with vehicle.  However, 
significantly lower hemoglobin and red cell counts showed that macrophage-depleted mice 
experienced relative anemia when compared to their vehicle-treated counterparts.  Most 
interestingly, dimerizer-treated mice demonstrated a marked reactive monocytosis, with a nearly 
5-fold increase in blood monocyte levels. 
Monocytic cells infiltrate tumors near blood vessels.  While preliminary analysis of the F4/80-
stained tumors showed a paucity of macrophages in the tumors of mice treated with AP20187, 
closer inspection told a more interesting story.  Near areas of high blood vessel density (Figure 
6), one could find relatively high numbers of F4/80+ cells migrating through the tumor.  Most of 
these cells demonstrated a younger, more monocyte-like morphology (black-center arrows), and 
many of the cells which displayed more mature morphologic character showed signs of blebbing 
and apoptosis (white-center arrows). 
Dimerizer treatment causes shift toward the classical, inflammatory, Gr-1hi monocyte subtype.  
We have taken note of recent work describing the characteristics of monocyte subpopulations 
(Strauss-Ayali, Conrad, and Mosser, 2007; Tacke, and Randolph, 2006), and feel it may relate to 
studies in the realm of tumor biology.  This work has shown that the Gr-1hi monocytes exhibit 
many pro-inflammatory properties.  If inflammation can drive cancer (Lin, and Karin, 2007), 
then any selection for or against this particular monocyte subset might affect tumor progression.  
Likewise, changes in the Gr-1hi, F4/80+ population within the tumor could also change the 
outcome (Sica, and Bronte, 2007).  We therefore wanted to show how treatment with dimerizer 
affected these monocyte and tumor macrophage subpopulations.  To do so, we isolated white 
blood cells from whole blood and from tumors collected from MAFIA+ mice treated with or 
without dimerizer.  We then stained these cells with markers that delineated the different 
subpopulations.  The results (Figure 7) show that treatment with dimerizer causes a shift toward 
the Gr-1hi phenotype monocyte in the blood, and the Gr-1hi MDSC in the tumor. 
Discussion 
Decades of studies have established that tumor-associated macrophages (TAMs) promote tumor 
progression by providing tumor growth factors (Lin, and Karin, 2007), blunting anti-tumor 
immune responses (Sica, and Bronte, 2007), and facilitating metastasis (Condeelis, and Pollard, 
2006).  Contrary to what we expected, our data show that elimination of macrophages by Fas-
induced apoptosis actually accelerated tumor growth and increased metastasis.   
We provide some evidence here that the mechanism underlying this observation may involve a 
reactive increase in a particular subset of cells.  So, while we have reduced or eliminated the 
majority of macrophages within the tumor environment, we may have actually increased the 
numbers of one particular subset of cells.   
While further study will be required to prove such a hypothesis, we suspect that these 
mesenchymal-derived stem cells, these Gr-1+ tumor associated macrophages, and the Gr-1hi 
inflammatory monocyte subset may be interrelated.  If such were truly the case, this could 
provide interesting therapeutic opportunities.  Our data suggest that it might be possible to 
eliminate the tumor-promoting activities of macrophages by targeting one particular subset.  This 
would likely reduce potential side effects and could make such treatments more effective, if the 
anti-tumor behaviors of other macrophage subsets were preserved. 
Materials and methods 
Mice.  MMTV-PyMT (Lin, Jones, et al, 2003) and MAFIA (Burnett, Kershen, et al, 2004) mice 
were obtained from Jackson Laboratories and bred at the animal facility at the Ohio State 
University College of Medicine.  All experiments were conducted in accordance with protocols 
approved by the OSU Institutional Animal Care and Use Committee.  Heterozygous PyMT+ 
male mice (on an FVB background) were bred to heterozygous or homozygous MAFIA+ female 
mice (on a B6 background).  Only F1 animals from these crosses were used to ensure 
background consistency and genetic identity.  Ear punch pieces were digested in accordance with 
the “Non-organic Tail DNA Extraction Protocol” published by Jackson Labs.  Mice were 
identified by PCR of these samples using the following primers: PyMT-Fv3, 5’- 
AATCCTTGTGTTGCTGAGCCCGATG -3’ and PyMT-Rv3, 5’- 
TCGAAATGAGCCCTCTGCAAATCCC -3’, to amplify a 255bp product corresponding to a 
portion of the polyomavirus middle T antigen protein, or MAFIA-F, 5’- AAG TTC ATC TGC 
ACC ACC G -3’ and MAFIA-R, 5’- TCC TTG AAG AAG ATG GTG CG -3’ to amplify a 
173bp product corresponding to the GFP portion of the transgene. 
Dimerizer.  AP20187 was kindly provided in lyophilized form by ARIAD Pharmaceuticals.  This 
was reconstituted with 100% ethanol to give a final concentration of 50 mg/ml.  This stock 
solution was separated into 50 μl aliquots and stored at -20°C.  “Dimerizer diluent” was prepared 
by creating a solution containing 4% ethanol, 10% PEG-400, and 1.7% Tween-20 in milliQ 
water, then sterilizing by filtration.  When ready for use, 50 μl aliquots were reconstituted with 
950 μl of dimerizer diluent to make a 2.5 mg/ml “1X” solution for induction treatments.  This 
concentration corresponds to a 100 ul dose for the average 25 gram mouse to receive 10 mg/kg.  
Maintenance doses were prepared by diluting this 1X solution 10-fold with dimerizer diluent. 
Macrophage ablation.  At 10 weeks ± 2 days of age, we randomized female PyMT+ mice with 
or without the MAFIA transgene to either dimerizer (AP20187, Ariad Pharmaceuticals) or 
vehicle treatment (dimerizer diluents) groups.  This time corresponded with the first appearance 
of palpable tumors, as determined in preliminary studies.  Treatment with dimerizer or vehicle 
began at this time continued for five weeks.  In accordance with the recommendations of the 
manufacturer, mice were treated with a five-day induction regimen consisting of daily tail vein 
injections at 10 mg/kg.  After induction therapy, mice were treated with 1 mg/kg of AP20187 
three times per week.  The last dose of dimerizer was given the evening before sacrifice (12-16 
hours prior). 
Immunohistochemistry.  After five weeks of treatment (at 15 weeks ±2 days of age), mice were 
euthanized and their organs harvested for analysis.  Tumors and spleens were fixed in 10% NBF, 
then embedded in paraffin and sectioned.  Optimal conditions for rat anti-mouse F4/80 (clone 
CI:A3-1, AbD Serotec) were protease digestion (protease 1, Ventana Medical Systems, Tucson 
AZ) for 4 minutes, dilutions of 1:100, dilution of the biotinylated anti-rat secondary antibody at 
1:200, and use of the DAB detection system from Enzo Diagnostics (Farmingdale, NY).   Total 
cell influx was analyzed by digital images captured of the entire tumors and quantified using 
Adobe Photoshop CS2 software. 
Lung Whole Mounts.  The methods we used for quantification of lung metastasis have been 
described previously (Jessen, Liu, et al, 2004).  Briefly, lungs removed immediately after 
euthanization were insufflated with PBS to equivalent pressures, then fixed in 10% formalin.  
The lungs were whole mounted and stained with hematoxylin.  These were then viewed under a 
steromicroscope to count the metastases, which appear as opacities in the cleared lung fields. 
Tumor Growth Assays (TGAs).  MET-1 Tumor cells (Borowsky, Namba, et al, 2005), a highly 
metastatic cell line derived from MMTV-PyMT mice, were stably transfected with a plasmid 
coding for DsRed.  The remaining details of the TGAs have beed described in detail previously 
(Sasser, Mundy, et al, 2007). 
Flow Cytometry.  Blood samples were cleared of red blood cells by 5 minute incubations using 
RBC lysis buffer (eBioscience).  Samples were pelleted then resuspended in FACS buffer 
containing FC Block (BD Pharmingen).  These samples were stained with PE-Cy7 anti-mouse 
F4/80, PerCP-Cy5.5 anti-mouse Gr-1 (both from BioLegend) and PI (BD Pharmingen).  Samples 
were then washed twice with FACS buffer and fixed with 1% paraformaldehyde.  Samples were 
run on a BD FACSAria machine and analysis performed using FCS Express software. 
For flow performed on tumor samples, pieces of tumor were minced in RPMI, then filtered 
through a cell strainer.  Buffy layers containing mostly lymphocytes and monocytes were 
separated by centrifugation over a lymphocyte separation medium gradient (cellgro).  These 
samples were then processed as described for blood. 
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Figure 1 
 
MAFIA mice.  A) The suicide gene contains a modified FK-binding protein coupled with the 
signaling portion of the Fas receptor.  The whole construct is anchored to the cell membrane by 
other modifications.   In the MAFIA mice, expression of this gene is limited to macrophages and 
a subset of neutrophils by placing the gene under the control of the M-CSF receptor promoter 
(fms).  B) In the absence of any dimerizing agent, the suicide gene remains inactive.  Upon 
administration of the pharmaceutical dimerizing agent AP20187, crosslinking of the receptors 
occurs, activating the Fas receptor domain and initiating the death cascade through the activation 
of caspase 3. 
Figure 2 
 
Administration of dimerizer eliminates macrophages from the tumors of MAFIA+, MMTV-
PyMT+ mice.  A)  Tumors were removed from MAFIA+, PyMT+ mice treated with vehicle or 
dimerizer.  Sections stained with antibodies directed at the F4/80 antigen reveal a relative paucity 
of macrophages throughout most of the tumors in mice treated with dimerizer.  B)  Sections of 
tumors from the same mice were stained by immunofluorescence and whole sections imaged 
using a fluorescent microscope fitted with a mechanized stage.  Fluorescent pixel density was 
calculated using Adobe Photoshop CS3 software.  For this analysis, n=3 mice per group, 
p=0.007 by Student’s T test. 
Figure 3 
 
Macrophage ablation increases tumor size and accelerates metastasis.  A) MAFIA+ or – mice 
were treated with vehicle or dimerizer according to the protocol outlined in methods.  At 
euthanasia, all tumors were resected from the mice and weighed to calculate total tumor burden.  
MAFIA+ mice treated with dimerizer averaged tumors that were slightly larger than those from 
macrophage normal animals.  For simplicity of analysis, and to avoid using unnecessary numbers 
of animals, mice are grouped into normal and macrophage ablated groups, though genotypes and 
conditions are shown on the graphs.  p=0.037 by Student’s T test, black lines show mean.  B) 
Lungs extracted from these same animals were processed and analyzed as outlined in methods.  
MAFIA+ mice treated with dimerizer averaged more metastases than those with normal 
macrophages (p=0.008 by Mann-Whitney U, chosen for extreme values and non-standard 




Tumor growth assays.  A) This graph shows data validating the use of the newly-developed Met-
1DsRed cell line in the three-dimensional tumor growth assay (TGA).  As the fluorescently-labeled 
cells multiply, the fluorescence intensity obtained by the plate reader increases proportionally.  
B) 12,500 Met-1DsRed cells per well were cultured alone (No Macs) or together with 125 (100), 
1,250 (10), 12,500 (1), or 125,000 (0.1) MAFIA+ bone marrow-derived macrophages.  After 48, 
all wells received dimerizer.  These studies show that dimerizer, the apoptotic process, and/or the 
apoptotic bodies do not have any mitogenic effects on this PyMT tumor cell line. Studies were 
repeated three times per data point with bone marrow macrophages derived from three different 
donors.  Error bars were omitted from this graph in the interest of clarity. 
Figure 5 
 
Macrophage ablation stimulates extramedullary hematopoiesis and a reactive monocytosis.  A)  
Spleens taken from MAFIA+ mice treated with or without dimerizer were stained with 
antibodies directed at the F4/80 antigen.  Macrophage-depleted mice show loss of splenic 
architecture and signs of extramedullary hematopoiesis (arrows).  This evidence suggests a 
demand for the production of hematopoietic cells that cannot be met by the bone marrow.  B)  
Graphs showing results of CBC analysis on the blood of tumor-bearing MAFIA+ mice treated 
for 5 weeks with vehicle or dimerizer.  Macrophage-depleted mice display some evidence of 
anemia with a large reactive increase in blood monocyte levels.  Statistical data shown represent 
Student’s T test performed on 8 and 6 mice per group, respectively. 
Figure 6 
 
Tumors from macrophage-depleted mice show evidence of monocyte infiltration.  Certain regions 
of the tumors from macrophage-depleted mice show patches of cells that stain positive for F4/80. 
Many of these patches, such as the one shown here, show a relatively large number of smaller, 
monocyte-like cells (black-center arrows).  Many of the cells with more mature morphologies 




Mononuclear cells isolated from whole blood or tumors show a shift toward the Gr-1hi 
phenotypes.  Here, monocytes isolated from tumor-bearing mice show a shift from the normal 
50-50 relative distribution of Gr-1hi and Gr-1lo populations (as evidenced by the gray graph 
showing monocytes isolated from mice treated with vehicle) to one enriched for the 
inflammatory, Gr-1hi cells (averaging a 26 to 74 ratio in depleted mice).  This trend continues in 
the mononuclear cells isolated from tumors, as evidenced in the graph on the right.  Within the 
tumors, population distributions change from one that is 3.7% Gr-1hi in mice treated with vehicle 
to one that is 29.6% Gr-1hi in mice treated with dimerizer. 
 
